Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer
| Autor: | Michael H Neale, Rosanne Allerton, Federica Di Nicolantonio, Louise A. Knight, Ian A. Cree, Christian M. Kurbacher, Richard J Osborne, Alan Lamont, Geraldine E Skailes |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Cancer Research medicine.medical_treatment Treosulfan Pharmacology Vinblastine Vinorelbine Ovarian tumor Adenosine Triphosphate Antineoplastic Combined Chemotherapy Protocols polycyclic compounds Humans Medicine Pharmacology (medical) Doxorubicin Antineoplastic Agents Alkylating Busulfan Aged Aged 80 and over Ovarian Neoplasms Cisplatin Drug Carriers Chemotherapy Antibiotics Antineoplastic business.industry Middle Aged medicine.disease Antineoplastic Agents Phytogenic Oncology Drug Design Liposomes Female Drug Screening Assays Antitumor Neoplasm Recurrence Local business Ovarian cancer Chemosensitivity assay medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 13:625-630 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/00001813-200207000-00009 |
| Popis: | Liposomal doxorubicin (Caelyx/Doxil) has been shown to be active in around 20% of recurrent ovarian cancers. As yet, there is little clinical data on combinations of existing agents with liposomal doxorubicin, despite considerable clinical experience with soluble doxorubicin in combination. In this study, we have used an ATP-based tumor chemosensitivity assay to determine the relative efficacy of high concentrations of doxorubicin tested in combination with cisplatin, treosulfan, 5-fluorouracil (5-FU) or vinorelbine against cells obtained from recurrent ovarian tumor tissue. The results show little enhancement of the efficacy of high concentrations of doxorubicin by 5-FU, cisplatin, or treosulfan. However, vinorelbine+liposomal doxorubicin showed additive inhibition, and this combination is worthy of further testing in clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|